Email updates

Keep up to date with the latest news and content from BMC Medicine and BioMed Central.

Journal App

google play app store
Open Access Commentary

OMICS-based personalized oncology: if it is worth doing, it is worth doing well!

Daniel F Hayes

Author Affiliations

Breast Oncology Program, University of Michigan Comprehensive Cancer Center, 6312 Cancer Center, 1500 E. Medical Center Drive, Ann Arbor, MI 48109-0942, USA

BMC Medicine 2013, 11:221  doi:10.1186/1741-7015-11-221

Published: 17 October 2013

Abstract

The era of Personalized Medicine implies getting the right treatment to the right patient at the right schedule and dose at the right time. Tumor biomarker tests are keys to accomplishing this goal successfully. However, much of the translational research regarding tumor biomarker tests has been haphazard, often using data and specimen sets of convenience and ignoring many of the principles of the scientific method. In papers published simultaneously in BMC Medicine and Nature, McShane and colleagues have proposed a checklist of criteria that should be followed by investigators planning to conduct prospective clinical trials directed towards generating high levels of evidence to demonstrate whether a tumor biomarker test has clinical utility for a specific context. These criteria were generated in response to a roadmap reported by a committee convened by the U.S. Institute of Medicine for generation of omics-based biomarker tests. Taken together with several other initiatives to increase the rigor of tumor biomarker research, these criteria will increase the perception of value for tumor biomarker test research and application in the clinic.

Please see related article: http://www.biomedcentral.com/1741-7015/11/220 webcite.

Keywords:
Tumor biomarker tests; Clinical investigation